MX2023002373A - Receptores de antígenos quiméricos bcma. - Google Patents
Receptores de antígenos quiméricos bcma.Info
- Publication number
- MX2023002373A MX2023002373A MX2023002373A MX2023002373A MX2023002373A MX 2023002373 A MX2023002373 A MX 2023002373A MX 2023002373 A MX2023002373 A MX 2023002373A MX 2023002373 A MX2023002373 A MX 2023002373A MX 2023002373 A MX2023002373 A MX 2023002373A
- Authority
- MX
- Mexico
- Prior art keywords
- chimeric antigen
- antigen receptors
- bcma chimeric
- bcma
- receptors
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La descripción proporciona composiciones mejoradas para terapias con linfocitos T adoptivas para afecciones relacionadas con células B.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063069784P | 2020-08-25 | 2020-08-25 | |
PCT/US2021/047290 WO2022046730A2 (en) | 2020-08-25 | 2021-08-24 | Bcma chimeric antigen receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002373A true MX2023002373A (es) | 2023-05-22 |
Family
ID=80353966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002373A MX2023002373A (es) | 2020-08-25 | 2021-08-24 | Receptores de antígenos quiméricos bcma. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230310604A1 (es) |
EP (1) | EP4204457A4 (es) |
JP (1) | JP2023539591A (es) |
KR (1) | KR20230053650A (es) |
CN (1) | CN116348496A (es) |
AU (1) | AU2021330958A1 (es) |
BR (1) | BR112023003337A2 (es) |
CA (1) | CA3191855A1 (es) |
IL (1) | IL300612A (es) |
MX (1) | MX2023002373A (es) |
WO (1) | WO2022046730A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117980326A (zh) | 2021-07-14 | 2024-05-03 | 2赛文缇生物公司 | 与来自抗体的结合结构域融合的经工程化的t细胞受体 |
WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2878449T3 (es) * | 2014-07-24 | 2021-11-18 | 2Seventy Bio Inc | Receptores antigénicos quiméricos de BCMA |
JP2019527696A (ja) * | 2016-08-01 | 2019-10-03 | ノバルティス アーゲー | プロm2マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置 |
CN112203725A (zh) * | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | Bcma嵌合抗原受体及其用途 |
WO2022261346A2 (en) * | 2021-06-09 | 2022-12-15 | Serotiny, Inc. | Synthetic receptor for conditional activation of immune cells |
-
2021
- 2021-08-24 BR BR112023003337A patent/BR112023003337A2/pt unknown
- 2021-08-24 AU AU2021330958A patent/AU2021330958A1/en active Pending
- 2021-08-24 EP EP21862543.2A patent/EP4204457A4/en active Pending
- 2021-08-24 WO PCT/US2021/047290 patent/WO2022046730A2/en active Application Filing
- 2021-08-24 MX MX2023002373A patent/MX2023002373A/es unknown
- 2021-08-24 US US18/023,232 patent/US20230310604A1/en active Pending
- 2021-08-24 IL IL300612A patent/IL300612A/en unknown
- 2021-08-24 CA CA3191855A patent/CA3191855A1/en active Pending
- 2021-08-24 JP JP2023513346A patent/JP2023539591A/ja active Pending
- 2021-08-24 KR KR1020237009062A patent/KR20230053650A/ko active Search and Examination
- 2021-08-24 CN CN202180070491.5A patent/CN116348496A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4204457A2 (en) | 2023-07-05 |
WO2022046730A9 (en) | 2022-04-21 |
IL300612A (en) | 2023-04-01 |
KR20230053650A (ko) | 2023-04-21 |
WO2022046730A2 (en) | 2022-03-03 |
CN116348496A (zh) | 2023-06-27 |
US20230310604A1 (en) | 2023-10-05 |
CA3191855A1 (en) | 2022-03-03 |
EP4204457A4 (en) | 2024-10-02 |
AU2021330958A1 (en) | 2023-05-04 |
JP2023539591A (ja) | 2023-09-15 |
BR112023003337A2 (pt) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001107A1 (es) | Receptor quimérico de citocinas. (divisional solicitud 201800415). | |
CL2022001374A1 (es) | Receptores de antígeno quimérico y usos de los mismos | |
SG11201906780SA (en) | Bcma-targeting antibody and use thereof | |
CA211013S (en) | Vaporizer device | |
MX2023002373A (es) | Receptores de antígenos quiméricos bcma. | |
EP4368641A3 (en) | Kappa myeloma antigen chimeric antigen receptors and uses thereof | |
SG11202006883QA (en) | Chimeric antigen receptors targeting cd70 | |
MX2021006181A (es) | Una capsula de bebida. | |
MX2022005152A (es) | Uso de receptores de antigenos quimericos anti-bcma. | |
EP4223269A3 (en) | Uses of anti-bcma chimeric antigen receptors | |
AU2018258581A8 (en) | RAF-degrading conjugate compounds | |
MX2019000985A (es) | Recomendacion de accesorio. | |
MX2009013035A (es) | Dispensador de fluidos. | |
EP3762430A4 (en) | DIMER ANTIGEN RECEPTORS (DAR) | |
MX2020009286A (es) | Antagonistas del receptor de adenosina y usos de los mismos. | |
CR20200404A (es) | Anticuerpos anti-klk5 y métodos de uso | |
EA202192146A1 (ru) | Антитела к клаудину 6 и их применение | |
MX2022008684A (es) | Anticuerpos que se unen a integrina avb8 y usos de los mismos. | |
EP4025227A4 (en) | DIMER ANTIGEN RECEPTORS (DAR) THAT BIND TO BCMA | |
CL2017001957U1 (es) | Almohadilla urinaria masculina. | |
MY197202A (en) | A liquid formulation of anti-tnf alpha antibody | |
SG11201900709QA (en) | Mixed cement | |
MX2024001608A (es) | Antagonistas de lpar1 y usos de estos. | |
CL2019001469S1 (es) | Cepillo de dientes. | |
MX2023013714A (es) | Anticuerpos anti-proteina accesoria del receptor de interleucina 1 (il-1). |